Letter

Adjuvant treatment with tamoxifen

BMJ 1996; 313 doi: 10.1136/bmj.313.7055.493c (Published 24 August 1996)
Cite this as: BMJ 1996;313:493.4

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Care is necessary

  1. R D Bulbrook, Former head
  1. clinical endocrinology laboratory, Imperial Cancer Research Fund Clachan, Dunlichity, Inverness IV1 2AN

    EDITOR,—Michael Baum and Jack Cuzick1 object to my comments about a clinical announcement by the National Cancer Institute that a trial comparing five years of adjuvant treatment with tamoxifen for breast cancer with a longer period of such treatment has been stopped.2 They say that the announcement is a “dubious and previously discredited process” (why?) and is based on unpublished data. Table 1 gives the data, which are available under the American Freedom of Information Act.

    View this table:
    • In this window
    • In a new window
    Table 1

    Data available from trial comparing short …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular